Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Investigators Tackle the Untapped Potential of Personalized Medicine

February 26th 2022

Improving patient outcomes is top of mind for investigators at John Theurer Cancer Center in Hackensack, New Jersey.

Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

February 8th 2022

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Serious Concerns Cloud Potential Benefit of Liquid Biopsy in Cancer Screening

February 3rd 2022

Maurie Markman, MD, explains the concerns surrounding liquid biopsies in cancer screening, and why regulatory agencies should be cautious and not approve any proposed molecularly based cancer diagnostic screening strategy until the tool is shown to effect cancer-specific survival compared with a control population not undergoing such testing.

Making Progress Against the Blood-Brain Barrier

January 31st 2022

Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier, a highly restrictive interface between the bloodstream and the brain that prevents most drugs from accessing the brain parenchyma.

Lorlatinib Approved in Europe for ALK+ Advanced NSCLC

January 28th 2022

The European Commission has granted a marketing authorization for lorlatinib for use as a single agent in the treatment of adult patients with ALK-positive advanced non–small cell lung cancer who did not receive a prior ALK inhibitor.

Next Steps for KRAS Inhibitors Focus on Tackling Resistance

January 17th 2022

The recent approval of sotorasib for the treatment of patients with advanced KRAS G12C–mutant non–small cell lung cancer marks a milestone for cancer therapy.

Targeting CD166 Represents a New Avenue of Attack for Breast Cancer

January 12th 2022

High expression of activated leukocyte cell adhesion molecule, also known as CD166, occurs in approximately 50% of patients with triple-negative breast cancer and up to 80% of patients with estrogen receptor– positive, HER2-negative breast cancer.

Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers

January 6th 2022

Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.

New Players Join Quest for a Therapeutic Foothold Against TGFβ

January 3rd 2022

Bintrafusp Alfa, a novel fusion protein designed to target the transforming growth factor beta pathway, racked up 3 clinical trial disappointments in less than a year, leaving the future of its development in question.

FDA Greenlights Companion Diagnostic for BRAF Inhibitors in Melanoma

December 8th 2021

The FDA has approved FoundationOne CDx for use as a companion diagnostic for 2 groups of current a future regulatory-approved treatments in melanoma, including single-agent BRAF inhibitors targeting BRAF V600E mutations and BRAF/MEK combination regimens targeting BRAF V600E or V600K mutations.

UAMS Winthrop P. Rockefeller Cancer Institute Pushes Liquid Biopsy Research Forward

November 30th 2021

The use of a routine blood test to assess and monitor patients with cancer, especially in a longitudinal manner, has long been the holy grail of cancer research.

Multigene Panel Testing Identifies Actionable Germline Mutations in Newly Diagnosed Endometrial Cancer

November 26th 2021

Investigators identified potentially actionable germline variants in 10% of unselected women with newly diagnosed endometrial cancer, supporting the use of upfront multigene panel testing for all in the population.

Dr. Ganesan on Leveraging Precision Medicine to Improve Cancer Care

November 22nd 2021

Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials.

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.

Dr. Albitar on the Importance of Obtaining Genomic Testing in Oncology

November 3rd 2021

Maher Albitar, MD, discusses the importance of obtaining genomic testing in oncology.

FDA Grants Partial Recognition to Memorial Sloan Kettering’s OncoKB Database

November 3rd 2021

The Food and Drug Administration has granted recognition to a partial listing of the Oncology Knowledge Base, a comprehensive precision oncology knowledge databased developed by investigators and physicians at Memorial Sloan Kettering Cancer Center.

Genomically-Guided Radiation Dosing Model Shows Promise in Various Cancer Types

November 3rd 2021

Radiation oncologists Jacob Scott, MD, DPhil, and Javier Torres-Roca, MD, discuss the benefits of using GARD in a pooled pan-cancer analysis and why there is a call to action to integrate GARD-based radiotherapy dosing in oncology.

Genomic Testing Cooperative Seeks to Increase Accessibility to Genomic Profiling Across Cancers

November 2nd 2021

Maher Albitar, MD, discusses the unmet needs with genomic testing that served as the impetus to start GTC, the process of becoming a partner with the organization, and the importance of genomic profiling for all patients with cancer.

Dr. Johnson on the Potential of TROP2 as a Target for All-Comers With Solid Tumors

October 29th 2021

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

RP-3500 Shows Promising Safety, Clinical Activity in Solid Tumors With Synthetic Lethal Genomic Alterations

October 27th 2021

The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.